A probiotic extract being developed from the human microbiome could be an option for the topical treatment of patients with atopic dermatitis, and could protect against pathogenic biofilms, new research shows.
Lead researcher Eva Berkes, MD, chief scientific officer for Quorum Innovations in Sarasota, Florida, explained that in terms of restoring the damaged skin barrier, the probiotic extract “worked very nicely, equivalently to dexamethasone, yet it is not a steroid.” Bobban Subhadra, PhD, director of research and development for the company added that the extract also showed “activity against pathogenic biofilms, and has anti-inflammatory effects.”
Read the original article here: Medscape
